10x Genomics Showcases Robust Innovation Pipeline at Xperience 2022 Event
For the Chromium single cell platform, Xperience 2022 featured several upcoming products designed to enable broad adoption of single cell methods, remove bottlenecks, and create more value for researchers around the world:
The single cell showcase also featured 5′ CRISPR, an extension to Single Cell Immune Profiling to make large-scale, functional genomics studies quicker and easier; and ATAC v2, an update to the Single Cell ATAC-seq workflow to boost sensitivity, while increasing discovery power and reducing costs. Both are planned to launch by mid-year.
Xperience 2022 also showcased the breadth of the Visium spatial analysis product roadmap, featuring several upcoming technologies focused on enabling more analytes, more samples, and more resolution:
Xperience 2022 provided a first look into Xenium, the company’s forthcoming in situ platform. The company expects the Xenium Analyzer will deliver targeted gene expression information at subcellular resolution at high sensitivity, and will be a complete end-to-end in situ solution: a robust instrument, consumables, panels, and software. Xenium is being developed as a high throughput platform that can run large cohorts of entire tissue sections without requiring selection of regions of interest. 10x Genomics expects to ship the Xenium Analyzer by the end of 2022.
“We plan to put the Xenium Analyzer in the hands of customers this year, marking the beginning of a revolution in tissue analysis, at the most fundamental level with unprecedented scale,” Hindson added. “With our Xenium platform for in situ analysis, RNA and proteins can be measured in the cells where they originated, still located in the native tissue. Our multi-year roadmap will usher in this powerful new capability and lead to an explosion of new data and insights to ultimately master biology and advance human health. Until then, we are relentlessly focused on this mission.”
To learn more about products showcased at Xperience 2022, please visit
10xgenomics.com/new-products. The event will also be hosted on February 24 for the Asia Pacific region, and registration is open at 10xgenomics.com/xperience.
About 10x Genomics
10x Genomics is a life science technology company building products to interrogate, understand and master biology to advance human health. The company’s integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. 10x Genomics products have been adopted by researchers around the world including in all of the top 100 global research institutions as ranked by Nature in 2020 based on publications and all of the top 20 global pharmaceutical companies by 2020 research and development spend and have been cited in over 3,300 research papers on discoveries ranging from oncology to immunology and neuroscience. The company’s patent portfolio comprises more than 1,300 issued patents and patent applications.
Disclosure Information
10x Genomics uses filings with the Securities and Exchange Commission, its website (www.10xgenomics.com), press releases, public conference calls, public webcasts and its social media accounts as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.
SOURCE 10x Genomics, Inc.